GlaxoSmithKline and Chroma Therapeutics have formed a collaboration to develop macrophage-targeted compounds using Chroma’s proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process. Chroma will undertake four discovery and development programs to identify small molecule therapeutics, including its macrophage-targeted HDAC inhibitor programme for inflammatory di...